Coenzyme Q10 and Heart Health: Latest Meta-Analysis

⚠️ IMPORTANT LEGAL NOTICE

These scientific studies are for informational purposes only.

The presented research results are NOT approved Health Claims under EU Regulation (EC) No 1924/2006. Only Health Claims officially approved by EFSA may be used for product advertising.

Non-approved Health Claims are legally impermissible and may lead to warnings.

✅ Check approved claims: [EU Health Claims Register](https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public/)

---

## Summary

A meta-analysis by Fan L et al. from 2023 investigates the cardioprotective effects of Coenzyme Q10 and was published in Frontiers in Cardiovascular Medicine.

Study Background

This systematic review analyzes randomized controlled trials on the effects of CoQ10 in patients with heart failure.

Key Findings

The meta-analysis shows: - Improvement of heart function: LVEF increased by 3-5% - Reduction of cardiovascular events: Significant risk reduction - Dosage: 100-300 mg daily - Form: Ubiquinol shows better bioavailability

Methodology

As a meta-analysis, this work combines data from 17 randomized controlled trials with over 1400 patients.

Practical Relevance for Dietary Supplement Manufacturers

These research results are relevant for: - Product development: Ubiquinol vs. ubiquinone - Study results: The research shows certain effects (no approved claims) - Dosage: 100-300 mg per day - Combination: Synergy with omega-3

Source

The full study is freely available on Europe PMC.

Authors: Fan L, Feng Y, Chen GC, Qin LQ, Fu CL, Chen LH Year: 2023 Journal: Frontiers in Cardiovascular Medicine PMCID: PMC10119896 PMID: 37123371

---

*Note: This summary is for informational purposes. The presented study results are not approved Health Claims. For detailed information, please consult the original source.*